Key result
Vericiguat is associated with a ~27% relative improvement in flow-mediated dilation for patients with HFrEF.
Why the study?
While vericiguat improves prognosis in patients with HFrEF and worsening heart failure, its effect on endothelial function assessed by flow-mediated dilation was not evaluated.
Does vericiguat improve endothelial function assessed by flow-mediated dilation in patients with HFrEF and worsening heart failure?
Does vericiguat improve endothelial function assessed by flow-mediated dilation in patients with HFrEF and worsening heart failure?
Three months of vericiguat therapy is associated with improved endothelial function in patients with HFrEF and worsening heart failure.
Should not yet change practice in HFrEF; leaves open endothelial benefits of vericiguat despite evidence against LVEF benefit.
Background Vericiguat, a soluble guanylate cyclase stimulator, has been shown to be effective in improving the prognosis of patients with heart failure with reduced ejection fraction (HFrEF) and worsening heart failure. We sought to evaluate possible changes in endothelial function assessed by flow-mediated dilation (FMD) in patients with HFrEF treated with vericiguat. Results Improved FMD values were found after 3 months of therapy with vericiguat (19 ± 11 vs. 15 ± 10% FMD, P = 0.04). FMD variation at follow-up was inversely related to baseline FMD values ( r = –0.52, P = 0.001). Major findings Three months of therapy with vericiguat in patients with HFrEF and worsening heart failure were associated with improved endothelial function assessed by FMD.
No takes yet. Share an insight, caveat, or question.
Correale et al. (2026) studied this question. Vericiguat therapy for three months significantly improved endothelial function in patients with HFrEF, increasing flow-mediated dilation from 15% to 19% (P=0.04).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: